Please login to the form below

Not currently logged in
Email:
Password:

Ziarco

This page shows the latest Ziarco news and features for those working in and with pharma, biotech and healthcare.

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

Novartis already has ZPL389 in its pipeline, a phase II ezcema treatment it gained with the acquisition of Ziarco two years ago.

Latest news

  • Novartis adds oral eczema drug with Ziarco acquisition Novartis adds oral eczema drug with Ziarco acquisition

    Expands dermatology pipeline with first-in-class, Pfizer-developed treatment prospect. Novartis has bolstered its dermatology portfolio by buying UK firm Ziarco, bolting on a first-in-class oral therapy for ... Ziarco's lead product is ZPL389, an

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Ziarco appoints Mike Grey to board of directors Ziarco appoints Mike Grey to board of directors

    I look forward to working with the Ziarco team to help grow the company and propel its product candidates forward.”. ... Ed Mathers, chairman of Ziarco, commented: “We are thrilled to welcome Mike to Ziarco's board of directors.

  • Former Pfizer R&D head LaMattina to advise Ziarco Former Pfizer R&D head LaMattina to advise Ziarco

    He previously spent 30 years at US pharma firm. UK-based biotech Ziarco has hired former head of R&D at Pfizer, Dr John LaMattina, as a strategic R&D adviser. ... In his new role, he will help Ziarco to advance its development strategies for its

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics